Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SABCS 2023 | TROPION-Breast04: Dato-DXd and durvalumab in TNBC or HR-low/HER2- breast cancer

Heather McArthur, MD, MPH, UT Southwestern Medical Center, Dallas, TX, provides an overview of the Phase III TROPION-Breast04 trial (NCT06112379), which assesses datopotamab deruxtecan (Dato-DXd), a TROP-2-directed antibody-drug conjugate (ADC), with durvalumab followed by adjuvant durvalumab in patients with HR-low/HER2- or triple negative breast cancer (TNBC). Patients will receive the investigational therapy or the standard of care based on the KEYNOTE-522 trial (NCT03036488). Dato-DXd has additionally shown promising results in the BEGONIA trial (NCT03742102). This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.